Checkpoint Therapeutics (NASDAQ:CKPT) posted its earnings results on Thursday. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.02), Zacks reports. Checkpoint Therapeutics had a negative net margin of 712.89% and a negative return on equity of 263.14%. The business had revenue of $0.28 million during the quarter, compared to analyst estimates of $0.70 million.
Shares of CKPT stock traded down $0.12 on Friday, hitting $1.78. 65,500 shares of the stock were exchanged, compared to its average volume of 80,778. The firm has a market capitalization of $72.57 million, a P/E ratio of -1.41 and a beta of 2.81. The business has a 50-day moving average of $2.08 and a 200 day moving average of $3.10. Checkpoint Therapeutics has a fifty-two week low of $1.50 and a fifty-two week high of $5.20.
Several research firms have recently weighed in on CKPT. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price objective on shares of Checkpoint Therapeutics in a research report on Monday, September 30th. ValuEngine raised Checkpoint Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st.
Checkpoint Therapeutics Company Profile
Checkpoint Therapeutics, Inc, an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's product candidates include CK-101 that in the phase 1/2 clinical trial for the treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer; and CK-301, a programmed death ligand-1 (PD-L1), which is in phase I clinical trial in patients with selected recurrent or metastatic cancers.
Featured Story: Accumulation/Distribution
Receive News & Ratings for Checkpoint Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkpoint Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.